ES2867048T3 - Derivados deuterados de ruxolitinib - Google Patents

Derivados deuterados de ruxolitinib Download PDF

Info

Publication number
ES2867048T3
ES2867048T3 ES18188152T ES18188152T ES2867048T3 ES 2867048 T3 ES2867048 T3 ES 2867048T3 ES 18188152 T ES18188152 T ES 18188152T ES 18188152 T ES18188152 T ES 18188152T ES 2867048 T3 ES2867048 T3 ES 2867048T3
Authority
ES
Spain
Prior art keywords
compound
myelofibrosis
therapeutic agent
mmol
deuterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18188152T
Other languages
English (en)
Spanish (es)
Inventor
I Robert Silverman
Julie F Liu
Adam J Morgan
Bhaumik Pandya
Scott L Harbeson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concert Pharmaceuticals Inc
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48699982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2867048(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2867048T3 publication Critical patent/ES2867048T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES18188152T 2012-06-15 2013-06-14 Derivados deuterados de ruxolitinib Active ES2867048T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261660428P 2012-06-15 2012-06-15
US201261678795P 2012-08-02 2012-08-02

Publications (1)

Publication Number Publication Date
ES2867048T3 true ES2867048T3 (es) 2021-10-20

Family

ID=48699982

Family Applications (2)

Application Number Title Priority Date Filing Date
ES21156398T Active ES3037872T3 (en) 2012-06-15 2013-06-14 Deuterated derivatives of ruxolitinib
ES18188152T Active ES2867048T3 (es) 2012-06-15 2013-06-14 Derivados deuterados de ruxolitinib

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES21156398T Active ES3037872T3 (en) 2012-06-15 2013-06-14 Deuterated derivatives of ruxolitinib

Country Status (19)

Country Link
US (7) US20150197525A1 (Direct)
EP (4) EP3450434B1 (Direct)
AU (3) AU2013274030B2 (Direct)
BR (1) BR122023027277A2 (Direct)
CA (1) CA2876306C (Direct)
DK (2) DK3450434T3 (Direct)
EA (1) EA201492287A1 (Direct)
ES (2) ES3037872T3 (Direct)
FI (1) FI3882249T3 (Direct)
HR (1) HRP20250965T1 (Direct)
IN (1) IN2014DN10670A (Direct)
LT (1) LT3882249T (Direct)
MX (2) MX373123B (Direct)
PL (2) PL3450434T3 (Direct)
PT (1) PT3882249T (Direct)
RS (1) RS67061B1 (Direct)
SI (1) SI3882249T1 (Direct)
SM (1) SMT202500302T1 (Direct)
WO (1) WO2013188783A1 (Direct)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54181B9 (sr) 2005-12-13 2020-01-31 Incyte Holdings Corp Heteroaril supstituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
PT3354652T (pt) 2010-03-10 2020-07-20 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
KR20140040819A (ko) 2011-06-20 2014-04-03 인사이트 코포레이션 Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
HUE055894T2 (hu) 2012-11-15 2021-12-28 Incyte Holdings Corp A ruxolitinib nyújtott felszabadulású dózisformái
UA120499C2 (uk) 2013-08-07 2019-12-26 Інсайт Корпорейшн Лікування захворювань із застосуванням лікарських форм з уповільненим вивільненням для інгібітора jak1
EP4233870A3 (en) * 2014-05-28 2024-01-24 Onco Tracker, Inc. Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
EP3325479B1 (en) 2015-06-03 2020-12-02 UWM Research Foundation, Inc. Ligands selective to alpha 6 subunit-containing gabaa receptors and their methods of use
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
CN108697700B (zh) 2016-02-04 2021-08-17 辛多美制药有限公司 氘代多潘立酮组合物和用于治疗病症的方法
EP3414235A4 (en) * 2016-02-12 2019-01-02 Vertex Pharmaceuticals (Europe) Limited Deuterium-modified cftr modulators
DK3452039T3 (da) 2016-05-04 2024-10-07 Sun Pharmaceutical Ind Inc Behandling af hårtabslidelser med deutererede jakhæmmere
EP4190318A1 (en) * 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
US20200281857A1 (en) 2017-11-22 2020-09-10 Dauntless 1, Inc. Therapeutic compound formulations
US20200353419A1 (en) 2017-11-22 2020-11-12 Dauntless 1, Inc. Membrane emulsification device for microsphere creation
US11179412B2 (en) * 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
BR112020018135A2 (pt) 2018-03-08 2020-12-22 Novartis Ag Uso de um anticorpo anti-p-selectina
JP7720697B2 (ja) 2018-03-30 2025-08-08 インサイト・コーポレイション Ｊａｋ阻害剤を用いる化膿性汗腺炎の治療
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
JP7378420B2 (ja) 2018-04-13 2023-11-13 インサイト・コーポレイション 移植片対宿主病のバイオマーカー
WO2020039401A1 (en) 2018-08-24 2020-02-27 Novartis Ag Treatment comprising il-1βeta binding antibodies and combinations thereof
CN120987947A (zh) * 2019-02-06 2025-11-21 太阳制药工业股份有限公司 用于制备对映异构体富集的jak抑制剂的方法
MA55201A (fr) 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
US11731947B2 (en) 2019-04-10 2023-08-22 University Of Notre Dame Du Lac Deuterated antimicrobial compounds
WO2020223640A1 (en) 2019-05-02 2020-11-05 Intel Corporation Quality of service (qos) in information centric networking (icn)
WO2020236950A1 (en) 2019-05-21 2020-11-26 Dauntless 1, Inc. Therapeutic microsphere formulations containing charged polymers
EP4041394A1 (en) 2019-09-16 2022-08-17 Novartis AG Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis
WO2021053489A1 (en) 2019-09-16 2021-03-25 Novartis Ag Use of an mdm2 inhibitor for the treatment of myelofibrosis
AU2020356575A1 (en) 2019-09-27 2022-04-14 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
JP2022551649A (ja) 2019-10-10 2022-12-12 インサイト・コーポレイション 移植片対宿主病のバイオマーカー
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
WO2021076124A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
CR20220280A (es) 2019-11-22 2022-09-02 Incyte Corp Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
MX2022014254A (es) 2020-05-13 2023-02-16 Disc Medicine Inc Anticuerpos anti-hemojuvelina (hjv) para tratar mielofibrosis.
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CA3194469A1 (en) 2020-08-12 2022-02-17 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
EP4225317A1 (en) 2020-10-08 2023-08-16 Novartis AG Use of an erk inhibitor for the treatment of myelofibrosis
AU2021372512A1 (en) 2020-10-28 2023-06-22 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
EP4247383A1 (en) * 2020-11-19 2023-09-27 Sol-Gel Technologies Ltd. Ruxolitinib or deuterated ruxolitinib composition and uses thereof
HRP20250528T1 (hr) 2020-12-04 2025-06-20 Incyte Corporation Jak inhibitor s analogom vitamina d za liječenje kožnih bolesti
KR20230157307A (ko) 2021-01-11 2023-11-16 인사이트 코포레이션 Jak 경로 억제제 및 rock 억제제를 포함하는 병용 요법
CN114853760B (zh) * 2021-02-03 2025-12-05 南京正大天晴制药有限公司 一种芦可替尼中间体的制备方法
WO2023018904A1 (en) 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
US20240307401A1 (en) 2021-08-12 2024-09-19 Sun Pharmaceeutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
CN113820413B (zh) * 2021-09-17 2023-04-07 重庆华邦胜凯制药有限公司 高效液相色谱法分离测定磷酸芦可替尼及杂质的方法
EP4518863A1 (en) 2022-05-04 2025-03-12 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
CN117384163A (zh) * 2022-07-05 2024-01-12 盛世泰科生物医药技术(苏州)股份有限公司 一种含偕二氟基的化合物及其制备方法和用途
WO2024196761A1 (en) * 2023-03-17 2024-09-26 Mayo Foundation For Medical Education And Research Use of oral jak kinase inhibitors to treat lichen planus
WO2024194352A1 (en) 2023-03-23 2024-09-26 Glaxosmithkline Intellectual Property (No.3) Limited Deuterated p2x3 modulators
US12364699B2 (en) 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate
US20250325664A1 (en) 2024-04-22 2025-10-23 Incyte Corporation Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CA2186371A1 (en) 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
ATE234299T1 (de) * 1999-12-03 2003-03-15 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
HU229938B1 (en) 2001-05-03 2015-01-28 Hoffmann La Roche Pharmaceutical dosage form of amorphous nelfinavir mesylate
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CN101076319A (zh) 2004-09-29 2007-11-21 科迪斯公司 稳定的非晶形雷帕霉素样化合物的药物剂型
JP2009511481A (ja) * 2005-10-06 2009-03-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 増強された治療特性を持つ、胃Ｈ＋，Ｋ＋−ＡＴＰａｓｅの重水素化阻害剤
RS54181B9 (sr) * 2005-12-13 2020-01-31 Incyte Holdings Corp Heteroaril supstituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
US20080103122A1 (en) * 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
SI2173752T2 (sl) * 2007-06-13 2022-09-30 Incyte Holdings Corporation Soli inhibitorja za janus kinazo (r)-3-(4-(7h-pirolo(2,3-d)pirimidin-4- il)-1h-pirazol-1-il)-3-ciklopentilpropannitrila
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EP2242493B1 (en) 2008-01-22 2013-06-05 Concert Pharmaceuticals Inc. Derivatives of gefitinib
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
HUE055894T2 (hu) * 2012-11-15 2021-12-28 Incyte Holdings Corp A ruxolitinib nyújtott felszabadulású dózisformái

Also Published As

Publication number Publication date
AU2013274030B2 (en) 2016-07-07
SI3882249T1 (sl) 2025-10-30
AU2018271227B2 (en) 2020-08-27
MX2014015185A (es) 2015-02-17
US20170239254A1 (en) 2017-08-24
EP3450434B1 (en) 2021-02-24
EP4606434A3 (en) 2025-12-03
AU2013274030A1 (en) 2015-01-22
CA2876306A1 (en) 2013-12-19
IN2014DN10670A (Direct) 2015-08-28
US20190308976A1 (en) 2019-10-10
WO2013188783A1 (en) 2013-12-19
US20230355629A1 (en) 2023-11-09
AU2016238877A1 (en) 2016-10-27
EP3882249A1 (en) 2021-09-22
FI3882249T3 (fi) 2025-08-11
PT3882249T (pt) 2025-08-06
LT3882249T (lt) 2025-08-25
ES3037872T3 (en) 2025-10-07
AU2018271227A1 (en) 2018-12-13
EP3450434A1 (en) 2019-03-06
US20150239896A1 (en) 2015-08-27
WO2013188783A8 (en) 2014-02-27
US20150197525A1 (en) 2015-07-16
AU2016238877B2 (en) 2018-08-30
PL3882249T3 (pl) 2025-09-08
DK3882249T3 (da) 2025-08-25
CA2876306C (en) 2024-02-20
PL3450434T3 (pl) 2021-10-04
EP4606434A2 (en) 2025-08-27
US20210330674A1 (en) 2021-10-28
MX360495B (es) 2018-11-06
DK3450434T3 (da) 2021-05-03
EP2861600A1 (en) 2015-04-22
EA201492287A1 (ru) 2015-07-30
SMT202500302T1 (it) 2025-09-12
US20250025467A1 (en) 2025-01-23
RS67061B1 (sr) 2025-08-29
EP3882249B1 (en) 2025-05-14
US9249149B2 (en) 2016-02-02
BR112014031204A2 (pt) 2017-06-27
MX373123B (es) 2020-04-27
BR122023027277A2 (pt) 2024-01-23
HRP20250965T1 (hr) 2025-10-10

Similar Documents

Publication Publication Date Title
ES2867048T3 (es) Derivados deuterados de ruxolitinib
AU2013296627B2 (en) Deuterated ibrutinib
JP6367545B2 (ja) ルキソリチニブの重水素化誘導体
AU2014235462B2 (en) Deuterated palbociclib
EP3492472A1 (en) Deuterated baricitinib with improved metabolic stability as jak1 and jak2 kinase inhibitor for treating e.g. rheumatoid arthritis
ES2672468T3 (es) Momelotinib deuterado
CN104725380B (zh) 卢索替尼的氘代衍生物
KR102433283B1 (ko) 룩소리티닙의 중수소화된 유도체
WO2012129381A1 (en) Deuterated preladenant
HK40060909B (en) Deuterated derivatives of ruxolitinib
HK40060909A (en) Deuterated derivatives of ruxolitinib
JP6830460B2 (ja) ルキソリチニブの重水素化誘導体
BR112014031204B1 (pt) Derivados deuterados de ruxolitinib e composição farmacêutica compreendendo os mesmos